SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andreas Helke who wrote (1960)10/1/1997 2:03:00 PM
From: Joe E.   of 6136
 
Good point that resistance will develop, although not necessarily with each patient. Resistance developed to antibacterials, but many lives were (and still are) extended. IMO same principal here, although faster.

Bottom line for drug manufacturers IMO: Hot drugs in this field are not annuities, and may play out before their patents expire. Drug manufacturers must continue to develop their drugs, not rest on their laurels. Still, these are the early days for protease inhibitors.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News